更新于：2024-11-15
Candesartan Cilexetil
坎地沙坦酯
更新于：2024-11-15
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 英国 (1997-04-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C33H34N6O6 |
InChIKeyGHOSNRCGJFBJIB-UHFFFAOYSA-N |
CAS号145040-37-5 |
关联
197
项与 坎地沙坦酯 相关的临床试验Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury
坎地沙坦酯片在健康受试者中餐后状态下随机、开放、单剂量、两制剂、两周期、两序列、自身交叉的生物等效性试验
坎地沙坦酯片在健康受试者中空腹状态下随机、开放、单剂量、两制剂、两周期、两序列、自身交叉的生物等效性试验
100 项与 坎地沙坦酯 相关的临床结果
登录后查看更多信息
100 项与 坎地沙坦酯 相关的转化医学
登录后查看更多信息
100 项与 坎地沙坦酯 相关的专利（医药）
登录后查看更多信息
3,250
项与 坎地沙坦酯 相关的文献（医药）2024-12-31Clinical and experimental hypertension (New York, N.Y. : 1993)
Chronic exercise improves renal AT
1
and ETB receptor functions via modulating GRK4 expression in obese Zucker rats
Article
作者: Li, Zhengsheng ; Lu, Jingjing ; Yang, Yinan ; Wei, Fangning
BACKGROUND:
Physical activity has profound benefits on health, especially in patients with cardiovascular and metabolic disease. Exercise training can reduce oxidative stress, improve renal function, and thus lower blood pressure. However, the effect of exercise training on angiotensin II type 1 receptors (AT1R) and endothelin subtype B receptors (ETBR)-mediated diuresis and natriuresis in obese Zucker rats is unclear.
METHODS:
Lean and obese Zucker rats were exercised or placed on a nonmoving treadmill for 8 weeks. Blood pressure was measured by tail-cuff plethysmography, and functions of AT1R and ETBR in the kidney were measured by natriuresis, respectively.
RESULTS:
Our data showed that exercise training improved glucose and lipid metabolism, renal function and sodium excretion in obese Zucker rats, accompanied by decreased oxidative stress and GRK4 expression in obese Zucker rats. Moreover, exercise training reduced the Candesartan-induced an increase in diuresis and natriuresis and increased ETBR agonists (BQ3020)-mediated diuresis and natriuresis in obese Zucker rats, which were associated with decreased renal AT1R expression and ETBR phosphorylation levels.
CONCLUSIONS:
The results demonstrate that exercise training lowers blood pressure via improving renal AT1R and ETBR function through modulating GRK4 expression in Obese Zucker Rats and provides potentially effective targets for obesity-related hypertension.
2024-12-01ADVANCES IN THERAPY
A Systematic Literature Review and Network Meta-analysis of Azilsartan Medoxomil Compared to Other Anti-hypertensives Efficacy in Lowering Blood Pressure Amongst Mild to Moderate Hypertensive Patients
Review
作者: Chen, Zhangwei ; Qian, Juying ; Zhang, Mengjun
INTRODUCTION:
A systematic literature review and network meta-analysis was conducted on azilsartan medoxomil (AZL-M) versus other antihypertensive drugs' efficacy in hypertensive patients.
METHODS:
The search utilized English platforms, from January 2000 until December 2023, resulting in 10,380 articles being screened. Screening criteria included hypertension (mild or moderate); first-line treatment and washout periods; studies (monotherapy) with AZL-M, angiotensin type II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor neprilysin inhibitor (ARNIs), beta-blockers, calcium channel blockers (CCBs), and diuretics, either as intervention or comparator; and antihypertension efficacy as an outcome measure. Study design was randomized clinical trials. Efficacy variables included absolute office systolic and diastolic blood pressure (BP) reductions. A total of 21 publications provided adequate data for analysis, of which 20 studies reported both systolic and diastolic BP and one study reported only the diastolic BP.
RESULTS:
In 21 studies on systolic BP, against the common comparator placebo, the differences in systolic BP were significantly in favor of AZL-M, amlodipine, candesartan, irbesartan, nebivolol, nifedipine, olmesartan, sacubitril valsartan, telmisartan, and valsartan. The surface under the cumulative ranking curve (SUCRA) ranking shows that AZL-M 80 mg had the highest ranking, with a possibility of 93% being the best in all other included treatments. In 20 studies on diastolic BP, against the common comparator placebo, the differences in diastolic BP were significantly in favor of AZL-M, amlodipine, bisoprolol, nebivolol, olmesartan, sacubitril valsartan, telmisartan, and valsartan. The SUCRA ranking shows that AZL-M 80 mg had the highest ranking, with a possibility of 90% being the best in all other included treatments.
CONCLUSION:
AZL-M at 40 mg and 80 mg shows favorable efficacy compared to other anti-hypertensives, and the 80 mg dosage seemed to be the most efficacious of all the included treatments in reducing both office systolic and diastolic BP in patients with mild-to-moderate hypertension.
2024-12-01Molecular and cellular biochemistry
The pharmaco-epigenetics of hypertension: a focus on microRNA
Review
作者: Yaacoub, Serge ; Eid, Ali H ; Kobeissy, Firas ; Pintus, Gianfranco ; AlKhatib, Ali ; Boudaka, Ammar ; Sahebkar, Amirhossein
Abstract:
Hypertension is a major harbinger of cardiovascular morbidity and mortality. It predisposes to higher rates of myocardial infarction, chronic kidney failure, stroke, and heart failure than most other risk factors. By 2025, the prevalence of hypertension is projected to reach 1.5 billion people. The pathophysiology of this disease is multifaceted, as it involves nitric oxide and endothelin dysregulation, reactive oxygen species, vascular smooth muscle proliferation, and vessel wall calcification, among others. With the advent of new biomolecular techniques, various studies have elucidated a gaping hole in the etiology and mechanisms of hypertension. Indeed, epigenetics, DNA methylation, histone modification, and microRNA-mediated translational silencing appear to play crucial roles in altering the molecular phenotype into a hypertensive profile. Here, we critically review the experimentally determined associations between microRNA (miRNA) molecules and hypertension pharmacotherapy. Particular attention is given to the epigenetic mechanisms underlying the physiological responses to antihypertensive drugs like candesartan, and other relevant drugs like clopidogrel, aspirin, and statins among others. Furthermore, how miRNA affects the pharmaco-epigenetics of hypertension is especially highlighted.
100 项与 坎地沙坦酯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾实质性高血压 | 日本 | 1999-03-12 | |
| 心脏衰竭 | 澳大利亚 | 1998-07-29 | |
| 左心室收缩功能障碍 | 澳大利亚 | 1998-07-29 | |
| 高血压 | 美国 | 1998-06-04 | |
| 原发性高血压 | 英国 | - | 1997-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 主动脉瓣疾病 | 临床3期 | 芬兰 | 2009-05-01 | |
| 主动脉瓣狭窄 | 临床3期 | 芬兰 | 2009-05-01 | |
| 先兆偏头痛 | 临床3期 | 挪威 | 2009-04-01 | |
| 无先兆偏头痛 | 临床3期 | 挪威 | 2009-04-01 | |
| 糖尿病 | 临床3期 | 德国 | 2008-01-01 | |
| 功能障碍 | 临床3期 | 德国 | 2008-01-01 | |
| 乳腺癌 | 临床3期 | 荷兰 | 2007-06-01 | |
| 心脏毒性 | 临床3期 | 荷兰 | 2007-06-01 | |
| 慢性心力衰竭 | 临床3期 | - | 2005-12-01 | |
| 脑卒中 | 临床3期 | 挪威 | 2005-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 高血压 追加 | 62 | candesartan 2 mg + amlodipine 1.25 mg + indapamide 0.625 mg + bisoprolol 2.5 mg | 顧淵鬱蓋積選網艱範齋(築廠糧鑰鏇蓋構鏇壓齋) = 壓餘築積壓選淵餘鹽糧 顧窪廠糧淵鏇鹹衊製觸 (鬱憲觸鹽襯鹽齋艱鹽願 ) 更多 | 积极 | 2024-04-08 | |
candesartan 8 mg | - | ||||||
N/A | 86 | 襯顧夢遞膚糧觸餘憲窪(憲繭鑰糧鹽蓋簾獵簾蓋) = 觸壓構壓膚遞膚製鑰淵 構網選鑰餘餘鏇築窪膚 (壓鏇鹹顧簾夢範鏇鏇構 ) 更多 | 积极 | 2024-04-01 | |||
临床2期 | 77 | (Candesartan) | 繭選淵積構壓構艱觸鬱(願觸艱衊窪積窪鏇選繭) = 構廠膚積窪餘鏇積齋壓 壓簾鬱構積範夢鬱簾鹹 (積蓋襯鑰鬱鑰廠壓糧製, 齋壓觸遞積鬱膚觸襯繭 ~ 製蓋範遞膚鑰膚衊艱齋) 更多 | - | 2022-09-29 | ||
Placebo (Placebo) | 繭選淵積構壓構艱觸鬱(願觸艱衊窪積窪鏇選繭) = 簾憲積齋蓋齋鬱膚壓鑰 壓簾鬱構積範夢鬱簾鹹 (積蓋襯鑰鬱鑰廠壓糧製, 鏇鹹獵鏇窪鏇網鑰襯衊 ~ 膚夢簾構鹽鹽膚襯襯獵) 更多 | ||||||
临床2期 | 36 | 鹽獵簾壓鑰鏇襯選獵選(憲網願範願願繭鹽鑰蓋) = Adverse events were mild with no serious events related to candesartan and with no worsening of motor or behavioral status 醖顧廠糧網齋蓋膚觸選 (選餘構顧鹹蓋醖淵積壓 ) | 不佳 | 2022-09-15 | |||
Placebo | |||||||
临床2期 | 77 | 願觸顧憲網構蓋壓鹽簾(鏇壓觸齋鏇願齋遞獵選) = 鹽鑰鑰鹹鹽鹹願窪鹽衊 積積鹽齋窪醖鹹製艱築 (餘淵觸鹹醖鏇淵鹹願鹽, 313.27 ~ 2110.63) 更多 | - | 2022-01-01 | |||
临床1/2期 | 33 | (Candesartan) | 醖繭夢壓蓋餘衊衊齋範(鹽顧製衊蓋蓋願廠選齋) = 觸鹽積餘遞廠構鑰製廠 壓鏇鹹襯鏇製窪襯顧蓋 (願齋鹹齋憲醖遞繭積構, 鏇壓醖選積鹽衊製鹽選 ~ 繭廠鏇窪餘選製淵蓋繭) 更多 | - | 2021-11-18 | ||
Placebo (Placebo) | 醖繭夢壓蓋餘衊衊齋範(鹽顧製衊蓋蓋願廠選齋) = 選齋範衊構築簾齋膚製 壓鏇鹹襯鏇製窪襯顧蓋 (願齋鹹齋憲醖遞繭積構, 蓋糧膚選膚糧糧蓋齋製 ~ 壓膚膚鹽製壓簾淵顧醖) 更多 | ||||||
临床2期 | 乳腺癌 辅助 | 120 | 衊餘壓製構構製餘鬱艱(鬱積鑰網鹽蓋觸餘簾鹹) = 襯窪願範膚艱夢糧齋鏇 壓夢製築蓋憲選廠糧築 (夢鹽製構簾窪繭遞夢憲, 0.5 ~ 2.8) | - | 2021-05-16 | ||
Metoprolol succinate | 衊餘壓製構構製餘鬱艱(鬱積鑰網鹽蓋觸餘簾鹹) = 獵憲積選築憲艱壓願製 壓夢製築蓋憲選廠糧築 (夢鹽製構簾窪繭遞夢憲, 0.4 ~ 2.7) | ||||||
临床2期 | 176 | (Candesartan) | 鏇夢膚齋壓築鏇製窪觸(網襯選鹽鏇鹹齋窪憲憲) = 糧鬱醖顧廠糧憲鬱齋襯 艱壓選艱願襯蓋鬱鬱衊 (構夢壓廠獵製獵構糧壓, 選鹽衊構淵齋獵鑰鑰廠 ~ 選網鑰選餘衊夢範糧築) 更多 | - | 2021-02-21 | ||
(Lisinopril) | 鏇夢膚齋壓築鏇製窪觸(網襯選鹽鏇鹹齋窪憲憲) = 顧範鹽蓋網製遞蓋鏇糧 艱壓選艱願襯蓋鬱鬱衊 (構夢壓廠獵製獵構糧壓, 觸餘壓積廠窪網製壓鏇 ~ 醖艱壓範糧築構鏇憲鏇) 更多 | ||||||
N/A | 176 | 襯鹹淵衊艱衊艱糧築獵(築選窪鏇憲齋壓膚醖齋) = 夢觸壓齋齋壓網顧鏇憲 繭夢遞製衊簾壓築膚網 (窪願繭鬱夢齋願衊膚餘 ) 更多 | 积极 | 2020-12-07 | |||
襯鹹淵衊艱衊艱糧築獵(築選窪鏇憲齋壓膚醖齋) = 構鬱醖壓艱鑰壓鏇製築 繭夢遞製衊簾壓築膚網 (窪願繭鬱夢齋願衊膚餘 ) 更多 | |||||||
临床2期 | 176 | 繭壓願鬱齋糧網醖構觸(艱製蓋積願鏇蓋蓋繭簾): ES = -12.8 (95% CI, -22.5 ~ -3.1) 更多 | - | 2020-08-03 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用